Form 4: Intensity Therapeutics CEO Awarded Stock Options

Intensity Therapeutics CEO Lewis H. Bender was granted stock options to purchase common stock, according to a recent SEC filing.

Summary

• Lewis H. Bender, the President and CEO of Intensity Therapeutics, Inc., was granted stock options on March 6, 2024.
• These options include the right to buy 464,805 shares of common stock at an exercise price of $5.19 per share.
• These options vest in four equal annual installments beginning March 6, 2024, subject to continued employment.
• Additionally, Bender was granted options to purchase 33,574 shares of common stock at an exercise price of $5.19 per share, which vested 100% on March 6, 2024.
• The options expire on March 6, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule for the larger option grant incentivizes continued service and performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation strategy.
• The size and vesting schedule of the options are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase shareholder value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates